IntelliCell BioSciences Files Patent Application for a New Research Technique

NEW YORK, July 23, 2012 /PRNewswire/ -- IntelliCell BioSciences, Inc. ("Company") (OTCQB: SVFC) announced today that it has filed a patent application for a new research technique the Company has developed for regenerative medicine.

The provisional patent, titled "ISOLATION OF STROMAL VASCULAR FRACTION FROM NON-LIVING ADIPOSE TISSUE USING ULTRASONIC CAVITATION" expands the field of cellular therapy, and specifically, research in adipose stromal vascular fraction (SVF).

For the first time SVF will be harvested from non-living adipose tissue for research and clinical purposes. Previously, only surgeons performing liposuction could supply samples of lipoaspirate cells that are then processed to yield SVF (or adipose stem cells or adipose derived regenerative cells (ADRCs).

According to IntelliCell's Chairman/CEO Steven Victor MD, "This will be transformational in the field of adipose stromal vascular fraction. SVF cells from adipose tissue will soon be readily available for researchers and institutions around the world to study and advance the field of cellular therapy with SVFs. This is an exciting discovery, yet there is significant work yet to be done before commercialization."

Robert Sexauer, EVP of Clinical Development, stated, "Much as organ donation has saved many, many lives, this process can lead to the development of new lifesaving treatments."

IntelliCell recognizes the future of cellular medicine in SVF therapy. These are vascular cells residing in the walls of all blood vessels in the body and the IntelliCell process will soon harvest these cells from non-living adipose tissue. In the future as part of this homologous process, with culturing, these cells will be cryopreserved according to blood type.

According to Bioinformant Worldwide LLC, "There is conclusive evidence that entering the stem cell research products market is fiscally worthwhile. Full-year 2011 analysis determines the size the stem cell research products market to be $2.59 billion, and the stem cell therapies market to be $3.13 billion, for a total of $5.72 billion. In addition, both markets are growing with double-digit growth. Producing stem cell research products thus represents a massive profit opportunity for research supply companies."

Dr. Victor said, "The future of medicine will reach an exciting stage when SVF will be stored in all major hospitals, similar to blood for transfusions, and these cells will be readily available to treat patients for a multitude of injuries and ailments (ie. orthopaedic, post myocardial infarction etc.). We believe this discovery will change the way patients are treated."

About IntelliCell BioSciences
IntelliCell is a pioneering regenerative medicine company focused on the expanding regenerative medical markets using adult autologous vascular cells (SVC's) derived from the blood vessels in the adult adipose tissue. IntelliCell Biosciences has developed its own patent pending protocol to separate adult autologous vascular cells from adipose tissue without the use of enzymes. IntelliCell will also be seeking to develop technology-licensing agreements with technology developers, universities, and international business entities.

Certain statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "will reach," "will change," "will soon," "should," "could," "would," "may," "can" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.

IntelliCell BioSciences, Inc.
Rubenstein Investor Relations
Contact: Tim Clemensen
Email Contact:
(212) 843-9337

SOURCE IntelliCell BioSciences, Inc.

Back to news